Kura Oncology, Inc. (NASDAQ:KURA) Receives $25.50 Consensus PT from Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twelve research firms that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $25.50.

A number of equities research analysts have issued reports on the company. Scotiabank cut their price target on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. JMP Securities restated a "market outperform" rating and set a $28.00 price target on shares of Kura Oncology in a research note on Thursday, February 6th. Jefferies Financial Group cut their price target on Kura Oncology from $32.00 to $28.00 and set a "buy" rating for the company in a research note on Thursday, November 21st. UBS Group cut their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Finally, BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th.

Insider Transactions at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company's stock, valued at $694,078.91. This represents a 5.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last ninety days. Corporate insiders own 5.50% of the company's stock.

Remove Ads

Institutional Trading of Kura Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Suvretta Capital Management LLC raised its holdings in Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock valued at $149,535,000 after buying an additional 583,155 shares during the period. Vanguard Group Inc. raised its holdings in Kura Oncology by 14.6% during the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock valued at $41,973,000 after buying an additional 615,211 shares during the period. RA Capital Management L.P. purchased a new stake in Kura Oncology during the 4th quarter valued at $38,769,000. Millennium Management LLC raised its holdings in Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock valued at $20,618,000 after buying an additional 1,521,954 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Kura Oncology by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after buying an additional 41,535 shares during the period.

Kura Oncology Stock Performance

NASDAQ:KURA traded up $0.05 during mid-day trading on Friday, reaching $7.34. The company's stock had a trading volume of 1,021,294 shares, compared to its average volume of 1,554,962. The firm's fifty day moving average price is $7.84 and its two-hundred day moving average price is $12.75. The stock has a market cap of $592.74 million, a P/E ratio of -3.11 and a beta of 0.85. Kura Oncology has a 12-month low of $6.79 and a 12-month high of $23.48. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. On average, equities analysts forecast that Kura Oncology will post -2.44 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.